Reata is a clinical-stage biopharmaceutical company that develops novel therapeutics for patients with serious or life-threatening diseases by targeting molecular pathways involved in the regulation of cellular metabolism and inflammation. Reata’s two most advanced clinical candidates (bardoxolone methyl and omaveloxolone) target the important transcription factor Nrf2 to restore mitochondrial function, reduce oxidative stress, and resolve inflammation.
S.H. Subramony, M.D., Professor of Neurology, University of Florida, Gainesville, FL, presented Baseline Characteristics in Part 2 of “MOXIe” Trial: A Study of the Efficacy and Safety of Omaveloxolone in Patients with Friedreich’s Ataxia.
Colin Meyer, M.D., Chief Medical Officer, Reata Pharmaceuticals, presented Rationale and Design of “CARDINAL”: A Phase 2/3 Study of the Efficacy and Safety of Bardoxolone Methyl in Patients with Alport Syndrome.